- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.03. | Spero halts development on another antibiotic in latest reprioritization | ||
| 28.03. | BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody | ||
| 27.03. | Senior NIH leader Tara Schwetz put on leave: Stat | ||
| 27.03. | Arbutus jettisons 57% of staff, ceases in-house research | ||
| 27.03. | Langer spin-out Lyndra Therapeutics begins winding down operations, lays off staff | ||
| 27.03. | RFK Jr. cuts 4,700 FDA and NIH jobs as HHS eliminates 'an entire alphabet soup of departments' | ||
| 27.03. | Equillium misses primary endpoint, plus 2 key secondaries, but still plans approval filing | ||
| 27.03. | Candel's lung cancer survival data light path toward pivotal trial in subpopulation | ||
| 27.03. | Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO | ||
| 27.03. | Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program | ||
| 26.03. | Despite raising $1B over past 5 years, ElevateBio lets go of 17% of workforce | ||
| 26.03. | Senate confirms research economist Jay Bhattacharya to lead the NIH | ||
| 26.03. | Ascletis slashes funding for former core programs in pivot to obesity | ||
| 26.03. | Wave's DMD drug remains on track in 48-week data ahead of FDA push next year | ||
| 26.03. | Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial | ||
| 26.03. | ImmuneOnco axes CD47 bispecific as pipeline prioritization pressures hit Chinese biotech | ||
| 25.03. | Cassava stops Alzheimer's program as simufilam fails another phase 3 | ||
| 25.03. | Merck & Co. pens $200M upfront deal for Hengrui's midstage heart disease med | ||
| 25.03. | Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan | ||
| 24.03. | Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return: Deloitte | ||
| 24.03. | UPDATE: DOGE removes 91 federal site closures from website, including 3 FDA facilities | ||
| 24.03. | Unity's eye treatment fails to match Eylea, though analysts still see a path forward | ||
| 24.03. | Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease | ||
| 24.03. | Mira seeks to buy Skny for its preclinical obesity, smoking cessation asset | ||
| 24.03. | Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
